Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus abemaciclib (ABE) in ER+/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): TACTIVE-U phase 1b/2 results.

Kisqali (ribociclib) - Novartis

Ibrance (palbociclib) - Pfizer

Veppanu (vepdegestrant) - Rigel Pharmaceuticals

Verzenio (abemaciclib) - Eli Lilly

fulvestrant - Generic mfg.

https://www.asco.org/abstracts-presentations/261204

Rachel Layman; Hechuan Wang; Shaparak Lonning; Noah Berkowitz; Yuanyuan Zhang; Joseph Kleha; Cynthia Ma; Katarzyna Jerzak; John Hilton; Pablo Tolosa Ortega; Alejandro Martinez Bueno; Stephen Chia; Meritxell Bellet; Jo Chien; Colombe Chappey

Apr 21, 2026